Patent EP0100982A2 successfully refreshed from Google Patents.
EP0100982A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Novel purified plasminogen activator, process for its production and thrombolytic composition containing it
Assignee: Asahi Kasei Corp
•
Filing: 1983-07-30
•
Granted: —
•
Expires: 2003-07-30
Abstract
Abstract A plasminogen activator obtained from a tissue cultured liquor of human normal tissue derived cells, e.g., human embryonic derived cells, human placenta derived cells etc., and having the following properties: a) molecular weight measured by gel filtration: 63,000 ± 10,000, b) isoelectric point : 7.0 - 8.5, c) affinity to fibrin: present, d) affinity to concanavalin A: present, e) optimum pH: 7 - 9.5, and f) stability : does not lose activity at 60°C for 10 hours but loses about 5% of activity at pH 2-3 at 98°C for a minute; a process for the production of the aforesaid plasminogen activator; and a thrombolytic composition containing the aforesaid plasminogen activator as an active ingredient are disclosed.
Inventors
- 👤 Toshihito Mori
- 👤 Hideo Yoshizaki
- 👤 Akio Hasegawa
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-30 05:46
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; A; A61; A61P; A61P7/00; A61P7/02; A61K; A61K38/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
81 words
A purified plasminogen activator obtained from 1 tissue cultured liquor of human normal tissue derived cells and having the following properties: a) molecular weight measured by gel filtration: 63,000 + 10,000, b) isoelectric point : 7.0 - 8.5, c) affinity to fibrin: present, d) affinity to concanavalin A: present, e) optimum pH: 7 - 9.5, and f) stability does not lose activity at 60°C for 10 hours but loses about 5% of activity at pH 2-3 at 98°C for a minute.
Claim 2
Dependent Claim
81 words
A purified plasminogen activator obtained from 1 tissue cultured liquor of human normal tissue derived cells and having the following properties: a) molecular weight measured by gel filtration: 63,000 + 10,000, b) isoelectric point : 7.0 - 8.5, c) affinity to fibrin: present, d) affinity to concanavalin A: present, e) optimum pH: 7 - 9.5, and f) stability does not lose activity at 60°C for 10 hours but loses about 5% of activity at pH 2-3 at 98°C for a minute.
Claim 3
Dependent Claim
97 words
A process for the production of a plasminogen activator having the following properties: a) molecular weight measured by gel filtration: 63,000 + 10,000, b) isoelectric point : 7.0 - 8.5, c) affinity to fibrin: present, d) affinity to concanavalin A: present, e) optimum pH: 7 - 9.5, and f) stability : does not lose activity at 60°C for 10 hours but loses about 5% of activity at pH 2-3 at 98°C for a minute, which comprises separating a fraction containing the plasminogen activator from a tissue cultured liquor of human normal tissue derived cells and purifying it.
Claim 4
Dependent Claim
97 words
A process for the production of a plasminogen activator having the following properties: a) molecular weight measured by gel filtration: 63,000 + 10,000, b) isoelectric point : 7.0 - 8.5, c) affinity to fibrin: present, d) affinity to concanavalin A: present, e) optimum pH: 7 - 9.5, and f) stability : does not lose activity at 60°C for 10 hours but loses about 5% of activity at pH 2-3 at 98°C for a minute, which comprises separating a fraction containing the plasminogen activator from a tissue cultured liquor of human normal tissue derived cells and purifying it.
Claim 5
Dependent Claim
63 words
A process for the production of a plasminogen activator as claimed in Claim 2, wherein the human normal tissue derived cell is selected from the group consisting of cells derived from human embryonic kidney, intestines, lungs, heart, ureter, skin or foreskin, or human whole embryo; human placenta derived cells; and cells derived from human kidney, intestines, lungs, thyroid gland, heart, ureter or ksin.
Claim 6
Dependent Claim
37 words
A process for the production of a plasminogen activator as claimed in Claim 3, wherein the human normal tissue derived cell is selected from the group consisting of cells derived from human embryonic kidney, lungs or foreskin.
Claim 7
Dependent Claim
41 words
A process for the production of a plasminogen activator as claimed in Claim 2, wherein the tissue cultured liquid is obtained by cultivating the human normal tissue derived cells in at least 0.2 ml of a nutrient solution per 100,000 cells.
Claim 8
Dependent Claim
34 words
A process for the production of a plasminogen activator as claimed in Claim 5, wherein the cultivating step is performed at a temperature of 25 to 40°C and a pH of 6 to 8.
Claim 9
Dependent Claim
34 words
A process for the production of a plasminogen activator as claimed in Claim 6, wherein the cultivation step is performed at a temperature of 35 to 38°C and a pH of 7.0 to 7.4.
Claim 10
Dependent Claim
78 words
A thrombolytic composition which contains a plasminogen activator having the following properties: a) molecular weight measured by gel filtration: 63,000 + 10,000, b) isoelectric point : 7.0 - 8.5, c) affinity to fibrin: present, d) affinity to concanavalin A: present, e) optimum pH: 7 - 9.5, and f) stability : does not lose activity at 60°C for 10 hours but loses about 5% of activity at pH 2-3 at 98°C for a minute, as a thrombolytic active ingredient.
Claim 11
Dependent Claim
78 words
A thrombolytic composition which contains a plasminogen activator having the following properties: a) molecular weight measured by gel filtration: 63,000 + 10,000, b) isoelectric point : 7.0 - 8.5, c) affinity to fibrin: present, d) affinity to concanavalin A: present, e) optimum pH: 7 - 9.5, and f) stability : does not lose activity at 60°C for 10 hours but loses about 5% of activity at pH 2-3 at 98°C for a minute, as a thrombolytic active ingredient.
Claim 12
Dependent Claim
85 words
A process for treating a patient requiring thrombolytic activity which comprises administering thereto an effective amount of a plasminogen activator having the following properties: a) molecular weight measured by gel filtration: 63,000 + 10,000, b) isoelectric point : 7.0 - 8.5, c) affinity to fibrin: present, d) affinity to concanavalin A: present, e) optimum pH: 7 - 9.5, and f) stability : does not lose activity at 60°C for 10 hours but loses about 5% of activity at pH 2-3 at 98°C for a minute.
Claim 13
Dependent Claim
85 words
A process for treating a patient requiring thrombolytic activity which comprises administering thereto an effective amount of a plasminogen activator having the following properties: a) molecular weight measured by gel filtration: 63,000 + 10,000, b) isoelectric point : 7.0 - 8.5, c) affinity to fibrin: present, d) affinity to concanavalin A: present, e) optimum pH: 7 - 9.5, and f) stability : does not lose activity at 60°C for 10 hours but loses about 5% of activity at pH 2-3 at 98°C for a minute.
Claim 14
Dependent Claim
30 words
A process for treating a patient requiring thrombolytic activity as claimed in Claim 9, wherein the plasminogen activator is administered in a dose of 200 to 1,000,000 units per day.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.